Cargando…

Proteomics, biomarkers, and HIV‐1: A current perspective

Despite more than three decades of extensive research, HIV‐1 infection although well controlled with cART, remains incurable. Multifactorial complexity of the viral life‐cycle poses great challenges in understanding molecular mechanisms underlying this infection and the development of biomarkers, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Donnelly, Maire Rose, Ciborowski, Pawel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666820/
https://www.ncbi.nlm.nih.gov/pubmed/26033875
http://dx.doi.org/10.1002/prca.201500002
_version_ 1782403744421380096
author Donnelly, Maire Rose
Ciborowski, Pawel
author_facet Donnelly, Maire Rose
Ciborowski, Pawel
author_sort Donnelly, Maire Rose
collection PubMed
description Despite more than three decades of extensive research, HIV‐1 infection although well controlled with cART, remains incurable. Multifactorial complexity of the viral life‐cycle poses great challenges in understanding molecular mechanisms underlying this infection and the development of biomarkers, which we hope will lead us to its eradication. For a more in‐depth understanding of how the virus interacts with host target cells, T cells and macrophages, proteomic profiling techniques that offer strategies to investigate the proteome in its entirety were employed. Here, we review proteomic studies related to HIV‐1 infection and discuss perspectives and limitations of proteomic and systems biology approaches in future studies.
format Online
Article
Text
id pubmed-4666820
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-46668202016-02-18 Proteomics, biomarkers, and HIV‐1: A current perspective Donnelly, Maire Rose Ciborowski, Pawel Proteomics Clin Appl Review Despite more than three decades of extensive research, HIV‐1 infection although well controlled with cART, remains incurable. Multifactorial complexity of the viral life‐cycle poses great challenges in understanding molecular mechanisms underlying this infection and the development of biomarkers, which we hope will lead us to its eradication. For a more in‐depth understanding of how the virus interacts with host target cells, T cells and macrophages, proteomic profiling techniques that offer strategies to investigate the proteome in its entirety were employed. Here, we review proteomic studies related to HIV‐1 infection and discuss perspectives and limitations of proteomic and systems biology approaches in future studies. John Wiley and Sons Inc. 2015-07-08 2016-02 /pmc/articles/PMC4666820/ /pubmed/26033875 http://dx.doi.org/10.1002/prca.201500002 Text en © 2015 The Authors. PROTEOMICS ‐ Clinical Applications Published by WILEY‐VCH Verlag GmbH & Co. KGaA This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review
Donnelly, Maire Rose
Ciborowski, Pawel
Proteomics, biomarkers, and HIV‐1: A current perspective
title Proteomics, biomarkers, and HIV‐1: A current perspective
title_full Proteomics, biomarkers, and HIV‐1: A current perspective
title_fullStr Proteomics, biomarkers, and HIV‐1: A current perspective
title_full_unstemmed Proteomics, biomarkers, and HIV‐1: A current perspective
title_short Proteomics, biomarkers, and HIV‐1: A current perspective
title_sort proteomics, biomarkers, and hiv‐1: a current perspective
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666820/
https://www.ncbi.nlm.nih.gov/pubmed/26033875
http://dx.doi.org/10.1002/prca.201500002
work_keys_str_mv AT donnellymairerose proteomicsbiomarkersandhiv1acurrentperspective
AT ciborowskipawel proteomicsbiomarkersandhiv1acurrentperspective